

South Carolina  
**Department of Health and Human Services**  
Post Office Box 8206  
Columbia, South Carolina 29202-8206

**Pharmacy and Therapeutics (P&T) Committee Meeting**  
**June 6, 2018**  
**MINUTES**

**1. Call to Order**

A meeting of the P&T Committee convened at 4:00 p.m. on Wednesday, June 6, 2018.

**2. Welcome**

Edward Behling, MD, called the meeting to order and welcomed members, guests, and staff members.

Dr. Behling opened the meeting by stating that the P&T Committee meetings are held in compliance with the Freedom of Information Act's (FOIA) mandate that the public is notified when the public's business is being done, and that furthermore, the public has been notified that this facility is accessible to individuals with disabilities, and special accommodations could have been provided if requested in advance.

**3. Committee Members Present:**

Thomas Phillips, RPh  
Philip Mubarak, MD  
Gregory Browning, MD

Tan Platt, MD  
Edward Behling, MD  
Kashyap Patel, MD

Joni Bollinger, MD

**SC DHHS Staff:**

Jim Bradford, MD  
Bryan Amick, PharmD  
Constance Holloway, JD  
Steven Ferrufino, MA, LPC-I, NCC, CCMHC

**Magellan Medicaid Admin:**

Lisa Correll, PharmD  
Lori Ash

**4. Discussion Topics**

**A. Committee Meeting Minutes, Wednesday, November 1, 2017**

The draft minutes from the previous P&T Committee meeting were emailed to the members so that they could review the document prior to the meeting. The minutes were approved unanimously.

**B. Public Comment**

<b>Company</b>	<b>Speaker</b>	<b>Drug/Class</b>
Alkermes	Anthony Richards, PharmD	Vivitrol/MAT
Indivior	Valerie Ng, PharmD	Sublocade/MAT
Alkermes	Anthony Richards, PharmD	Aristada/Long Acting Inj Antipsychotics
J&J	Brian Macomson, PharmD	Invega/Long Acting Inj Antipsychotics

**C. Drug Classes for Review**

Lisa Correll led the discussion for the following drug classes:

*Class for Re-Review*

- Long Acting Injectable Antipsychotics
- Medication Assisted Treatment (MAT)

*Class for Review*

- Medication Assisted Treatment (MAT)

The chart below represents the recommendations from the P & T Committee:

<b>MEDICATION ASSISTED TREATMENT (MAT)</b>	
<b>Preferred</b>	<b>Non-Preferred</b>
Buprenorphine (SL) Buprenorphine/naloxone (SL tab) Sublocade (buprenorphine injection) Suboxone Film (buprenorphine/naloxone) Vivitrol (naltrexone injection)	Bunavail (buprenorphine/naloxone buccal film) Probuphine (buprenorphine: medical arm implant) Zubsolv (buprenorphine/naloxone SL tabs)

<b>LONG ACTING INJECTABLE ANTIPSYCHOTICS</b>	
<b>Preferred</b>	<b>Non-Preferred</b>
Abilify Maintenna Aristada‡ Invega Sustenna/Trinza Risperdal Consta	Zyprexa Relprevv

‡ Indicates “Added as Preferred”

+ Indicates “Moved to Non-Preferred”

5. **Old Business**

None

6. **New Business**

Lisa presented new drugs to market. Bryan provided information on policy updates.

The Prescription Drug Management Program in SC:

(1) Policy updates regarding Opioids/MAT.

(2) SC will adopt preferred products, MAT, on the PDL.

(3) These guidelines will be adopted for both the MCO and FFS populations.

(4) Pilot program with MUSC/DAODAS to expand MAT in Emergency Rooms. The pilot will include a large hospital in the Myrtle Beach/Horry County area as well as other potential locations.

(5) Role of methadone clinic in pregnant women

(6) SC Medicaid has an Opioid Workgroup led by Steven Ferrufino

(7) SC is making earnest efforts to evaluate alternative pain management treatments including acupuncture and chiropractic care.

Agency reimbursement has followed 2009 Medicare benchmarks and has not been updated. There will be modernization and consolidation over the next 18 to 24 months. SC will move from 9-12 fee schedules to 3 and be more consistent with commercial payers.

Bryan updated the committee on the required annual Medicaid revalidation efforts. Those Members who did not return their required documentation within the 10 month period lost their eligibility. Should they return the documentation, they will become eligible effective July 1 and will be FFS initially for the initial 30-60 days.

7. **Resolved Items**

Recommendations regarding PDL status for drugs in the following classes were approved for submission to DHHS.

*Class for Re-Review*

Long Acting Injectable Antipsychotics

*Class for Review*

Medication Assisted Treatment (MAT)

8. **Closing Comments**

The next meeting will be held on Wednesday, September 5, 2018, at 4:00 p.m.

9. **Adjournment**

The meeting adjourned at 5:54p.m.